Capstone Investment Advisors
AUPH icon

Capstone Investment Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

Capstone Investment Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-31,458
Closed -$158K – 2079
2024
Q1 		$158K Buy
+31,458
New +$213K ﹤0.01% 2062

Other funds holding AUPH

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Capstone Investment Advisors's AUPH Position: Q2 2024 in Review

Capstone Investment Advisors sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2024, closing a stake of 31,458 shares — an estimated $158K sold.

Capstone Investment Advisors first reported a position in AUPH in Q1 2024 and held it in 1 quarter. The position peaked at $158K in Q1 2024. 171 funds tracked by Wall St. Rank hold AUPH as of Q2 2024.

  • Capstone Investment Advisors reported no remaining Aurinia Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Capstone Investment Advisors sold 31,458 Aurinia Pharmaceuticals shares in Q2 2024, an estimated $158K.
  • Capstone Investment Advisors first reported a position in Aurinia Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Capstone Investment Advisors's Aurinia Pharmaceuticals position peaked at $158K in Q1 2024.
  • 171 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2024.

Based on Capstone Investment Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.